Not much of a poster here in recent years, but have been in DXB since 2016.
The inconclusive result in DKD the Phase 2 trial in 2020 was a disappointment (more a frustration since it might well have been the result of DMX-200 providing unexpected residual benefit post dosing). Dimerix took this in its stride - DKD on the backburner and full steam ahead with FSGS.
Now we are at another inflection point: if the current trial results are positive and the FDA approves Phase 3, we could see a step change in Dimerix - not only running the FSGS trial, but also having the resources to revisit DKD and maybe even start pre-clinical work on DMX-700. DKD itself is a huge potential market.
Not much of a poster here in recent years, but have been in DXB...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
64.5¢ |
Change
0.065(11.2%) |
Mkt cap ! $354.5M | |||
| Open | High | Low | Value | Volume |
| 59.0¢ | 65.0¢ | 58.0¢ | $3.696M | 5.951M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 64.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 65.0¢ | 109360 | 4 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
64.5¢ |
Change
0.065 ( 12.4 %) |
||||
| Open | High | Low | Volume | ||
| 59.0¢ | 65.5¢ | 58.5¢ | 3782284 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| DXB (ASX) Chart |